Literature DB >> 32815289

Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies.

Giovanni B Frisoni1,2, José Luis Molinuevo3, Daniele Altomare1,2, Emmanuel Carrera4, Frederik Barkhof5,6, Johannes Berkhof7, Julien Delrieu8,9, Bruno Dubois10, Miia Kivipelto11,12,13,14, Agneta Nordberg11,12, Jonathan M Schott15, Wiesje M van der Flier7,16, Bruno Vellas8,9, Frank Jessen17,18,19, Philip Scheltens16, Craig Ritchie20.   

Abstract

Empirical evidence suggests that a fair proportion of dementia cases are preventable, that some preventive actions can be taken immediately, and others may soon be implemented. Primary prevention may target cognitively normal persons with modifiable risk factors through lifestyle and multiple domain interventions (including general cardiovascular health). While the effect on individuals may be modest, it might have a large societal impact by decreasing overall dementia incidence by up to 35%. Secondary prevention will target cognitively normal persons at high risk of dementia due to Alzheimer's disease pathology with future anti-amyloid, anti-tau, or other drugs. This approach is likely to have major benefits to both individuals and society. Memory clinics will need structural and functional changes to adapt to novel technologies and increased patients' demands, and brand-new services may need to be developed with specific skills on risk profiling, risk communication, and personalized risk reduction plans.
© 2020 the Alzheimer's Association.

Entities:  

Year:  2020        PMID: 32815289     DOI: 10.1002/alz.12132

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  5 in total

1.  Multidomain trials to prevent dementia: addressing methodological challenges.

Authors:  Manuel Montero-Odasso; G Y Zou; Nellie Kamkar; Howard H Feldman; Sylvie Belleville; Howard Chertkow; Haakon B Nygaard; Surim Son; Mark Speechley
Journal:  Alzheimers Res Ther       Date:  2022-07-11       Impact factor: 8.823

2.  The Cognitive Online Self-Test Amsterdam (COST-A): Establishing norm scores in a community-dwelling population.

Authors:  Leonie N C Visser; Mark A Dubbelman; Merike Verrijp; Lisa Wanders; Sophie Pelt; Marissa D Zwan; Dick H J Thijssen; Hans Wouters; Sietske A M Sikkes; Hein P J van Hout; Wiesje M van der Flier
Journal:  Alzheimers Dement (Amst)       Date:  2021-09-14

Review 3.  Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services-part 2 of 6.

Authors:  Janice M Ranson; Timothy Rittman; Shabina Hayat; Carol Brayne; Frank Jessen; Kaj Blennow; Cornelia van Duijn; Frederik Barkhof; Eugene Tang; Catherine J Mummery; Blossom C M Stephan; Daniele Altomare; Giovanni B Frisoni; Federica Ribaldi; José Luis Molinuevo; Philip Scheltens; David J Llewellyn
Journal:  Alzheimers Res Ther       Date:  2021-10-11       Impact factor: 6.982

4.  Island Study Linking Aging and Neurodegenerative Disease (ISLAND) Targeting Dementia Risk Reduction: Protocol for a Prospective Web-Based Cohort Study.

Authors:  Larissa Bartlett; Kathleen Doherty; Maree Farrow; Sarang Kim; Edward Hill; Anna King; Jane Alty; Claire Eccleston; Alex Kitsos; Aidan Bindoff; James C Vickers
Journal:  JMIR Res Protoc       Date:  2022-03-01

5.  Psychographic Segmentation: Another Lever for Precision Population Brain Health.

Authors:  Erin Smith; Agustin Ibanez; Helen Lavretsky; Michael Berk; Harris A Eyre
Journal:  Front Aging Neurosci       Date:  2021-12-08       Impact factor: 5.750

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.